Streetbeat News

Products Services

NVDA

SSNLF

TSM

Nvidia Corp (NVDA) is making headlines for its continued expansion in China and AI endeavors. The company plans to introduce three new chips in China to balance U.S. technology sanctions and its leading market. Nvidia CEO Jensen Huang praised Taiwan Semiconductor Manufacturing Co (TSM) founder Morris Chang for his pivotal role in Nvidia's success. NVDA shares traded higher by 0.37% at $471.25 premarket on the last check Friday.

Portfolio Pulse from Anusuya Lahiri

November 10, 2023 | 12:53 pm

MRTX

Mirati Therapeutics has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for its drug Krazati (Adagrasib) as a targeted treatment for patients with advanced non-small cell lung cancer with a KRASG12C mutation. This follows a re-examination procedure.

Portfolio Pulse from Benzinga Newsdesk

November 10, 2023 | 12:46 pm

MRK

The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of Merck's Keytruda in combination with gemcitabine and cisplatin for the treatment of locally advanced unresectable or metastatic biliary tract cancer.

Portfolio Pulse from Benzinga Newsdesk

November 10, 2023 | 12:43 pm

OCGN

Ocugen has announced the first patient dosing in its Phase 1/2 clinical trial for OCU410ST, a modifier gene therapy for Stargardt disease, which directly affects the retina. This marks a significant step in the company's research and development efforts.

Portfolio Pulse from Benzinga Newsdesk

November 10, 2023 | 12:37 pm

PCRX

Pacira Pharmaceuticals has announced that the FDA has approved the expanded label of its product, EXPAREL, to include two additional nerve block indications. This will significantly extend its reach within more than 3 million lower extremity procedures.

Portfolio Pulse from Benzinga Newsdesk

November 10, 2023 | 12:33 pm

LYEL

Lyell Immunopharma, Inc. (NASDAQ:LYEL) shares are trading higher after the company announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to LYL845 for the treatment of patients with stage IIB-IV melanoma. LYL845 is currently being investigated in a Phase 1 clinical trial. Initial data from the trial are expected in 2024.

Portfolio Pulse from Nabaparna Bhattacharya

November 10, 2023 | 12:30 pm

AZN

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for AstraZeneca's Omjjara for the treatment of Myelofibrosis. The article does not mention GSK or VGK.

Portfolio Pulse from Charles Gross

November 10, 2023 | 12:21 pm

AKTS

Akoustis Technologies has received a purchase order for three BAW filter designs from a customer in the 5G mobile and Wi-Fi router RF front-end market. The company's stock symbol is AKTS.

Portfolio Pulse from Benzinga Newsdesk

November 10, 2023 | 12:08 pm

AAOI

Applied Optoelectronics has entered into an exclusive distribution agreement with Digicomm International. Under the agreement, Digicomm will be the exclusive go-to-market supplier of AOI's Quantum12 Cable Amplifiers.

Portfolio Pulse from Benzinga Newsdesk

November 10, 2023 | 12:07 pm

KZIA

Kazia Therapeutics has announced the publication of preclinical data on Paxalisib, a product of its research collaboration with the Huntsman Cancer Institute at the University of Utah. The data, published in Molecular Cancer Therapeutics, highlights the potential of Paxalisib in cancer treatment.

Portfolio Pulse from Benzinga Newsdesk

November 10, 2023 | 12:06 pm